SecBot SecBot

ZYME drug pipeline

Zymeworks Inc. · 4 rated drugs
$26.24
−0.9% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.5%
1-day, median of 10 events
IV rank
No data
No current options data
Rated drugs
4
1 mixed · 3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed (FDA approved November 2018; China NMPA approved June 2025).

YUPELRI revefenacin Updated Nov 9

What to watch

YUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.

Bull case
  • YUPELRI is the first and only FDA-approved once-daily nebulized LAMA for COPD maintenance treatment, occupying a unique niche for patients who cannot use dry-powder or mist inhalers.
  • YUPELRI collaboration revenue grew 15% year-over-year in Q1 2026 ($17.7M), showing steady commercial momentum.
  • China NMPA approval was granted in June 2025, opening a large new market; Viatris handles ex-U.S. commercialization.
Bear case
  • YUPELRI faces entrenched competition from Spiriva HandiHaler (tiotropium), the market-leading LAMA; a Phase 4 head-to-head study (PIFR-2) failed to show a statistically significant difference on the primary endpoint of trough FEV1 at Day 85.
  • Generic entry is possible on or after April 23, 2039 per a patent settlement with Teva, which could eventually erode U.S. market share.
  • As a nebulized therapy, YUPELRI targets a narrower subset of COPD patients than dry-powder inhalers, limiting total addressable market.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).

Ziihera zanidatamab Updated Nov 9

What to watch

Ziihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.

Bull case
  • Ziihera is a first-in-class HER2-targeted bispecific antibody that binds two distinct HER2 epitopes, showing statistically significant overall survival benefit over trastuzumab in Phase 3 HERIZON-GEA-01 (median OS 26.4 vs 19.2 months), published in the New England Journal of Medicine.
  • The drug has secured two FDA approvals in under two years (BTC in Nov 2024, GEA in Aug 2026) and received Breakthrough Therapy Designation for HER2+ colorectal cancer in August 2026, opening a large addressable market.
  • Jazz Pharmaceuticals sees $3B-$5B peak sales potential for Ziihera, and Zymeworks has fortified its balance sheet with a $250M royalty-backed note from Royalty Pharma plus a $55M upfront from the Roche ZW209 deal.
Bear case
  • Ziihera faces entrenched competition from trastuzumab (Herceptin), which has been the standard-of-care HER2 agent for over a decade in gastric cancer, and from Enhertu (trastuzumab deruxtecan) in later-line settings.
  • Zymeworks does not directly control Ziihera's commercialization; Jazz Pharmaceuticals and BeOne Medicines hold the marketing rights, so Zymeworks' revenue is limited to royalties and milestones, capping upside.
  • The Q3 2026 earnings release noted an EPS miss of -5% versus estimates, and the stock trades near its 52-week high, suggesting much of the good news may already be priced in.
◆ mixed
Impact
PhasePhase 1
Time to marketZW191 is in Phase 1 with no registrational trial design announced. Assuming successful Phase 1 completion, a Phase 2/3 registrational trial would likely start in 2027, putting a potential FDA submission several years away, likely 2029 or later.

ZW191 Updated Nov 12

What to watch

The next catalyst for ZW191 is likely updated Phase 1 data at a medical conference in 2027 or news of Phase 2/registrational trial initiation. Zymeworks reports Q4 2026 earnings in early 2027, which may include a pipeline update. The strong ESMO 2026 response rate (64.5%) supports advancement, but the drug remains early-stage with no hard binary catalyst on the calendar.

Bull case
  • ZW191 showed a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated platinum-resistant ovarian cancer patients at ESMO 2026, a compelling efficacy signal for an early-phase trial.
  • The drug demonstrated activity across all FRα expression levels, potentially broadening the addressable patient population versus Elahere, which is restricted to high FRα expressers.
  • ZW191 uses a proprietary topoisomerase I inhibitor payload (ZD06519) with a high drug-to-antibody ratio, a differentiated mechanism from Elahere's maytansinoid payload.
Bear case
  • ZW191 is still in Phase 1, years from potential approval, with no registrational trial design or start date announced as of November 2026.
  • The FRα-targeted ADC space has a formidable competitor: AbbVie's Elahere (mirvetuximab soravtansine) is already FDA-approved for FRα-positive platinum-resistant ovarian cancer, creating a high bar for differentiation.
  • Phase 1 data are from a small, non-randomized sample; response rates often shrink in larger, more rigorous trials.
● neutral
Impact
PhasePhase 1
Time to marketUnknown — ZW209 has just entered Phase 1 trials. If successful, a potential approval would likely be 5+ years away given the early stage of development.

ZW209 Updated Oct 23

What to watch

Watch for HSR clearance of the Roche deal, which triggers the $55M upfront payment to Zymeworks. The next major catalyst for ZW209 specifically will be Phase 1a data readout and the Phase 1b initiation milestone ($40M). ZW209 is a small part of Zymeworks' broader story, the company's value is more driven by Ziihera (zanidatamab) royalties and the Theravance acquisition.

Bull case
  • Roche, one of the world's largest pharma companies, signed an exclusive global license for ZW209, providing strong external validation of Zymeworks' TriTCE platform
  • Zymeworks receives $55M upfront (post-HSR) plus $40M upon Phase 1b initiation, with up to $718M in milestones and tiered high-single-digit to mid-teen royalties
  • Roche funds the Phase 1a trial and takes over all subsequent development, meaning Zymeworks gets upside with no further spend on ZW209
Bear case
  • ZW209 is preclinical/Phase 1, clinical failure risk is very high, as most T-cell engagers fail in early development
  • Roche can terminate the agreement at will with written notice, per the 8-K filing
  • DLL3-targeted therapies have had mixed results (e.g., Amgen's tarlatamab is approved but others have failed), and ZW209's trispecific format adds complexity

Past FDA events & how the stock moved

10 events
DateDrugEvent1 day5 days
Aug 25, 2026ZiiheraPDUFA decision+1.9%+3.1%
Aug 25, 2026ZiiheraApproval+1.9%+3.1%
Aug 25, 2026ZiiheraPriority review+1.9%+3.1%
Aug 25, 2026ZiiheraBreakthrough designation+1.9%+3.1%
Aug 6, 2026ZiiheraBreakthrough designation+0.2%+9.6%
May 7, 2026ZiiheraBreakthrough designation−13.5%−13.2%
Apr 1, 2026ZiiheraPriority review+3.0%+9.2%
Apr 1, 2026ZiiheraNDA filed+3.0%+9.2%
Apr 1, 2026ZiiheraBLA filed+3.0%+9.2%
Apr 1, 2026ZiiheraBreakthrough designation+3.0%+9.2%